• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virol J . Optimization and validation of RT-LAMP assay for diagnosis of SARS-CoV2 including the globally dominant Delta variant

tetano

Editor, Senior Moderator
Virol J


. 2021 Aug 30;18(1):178.
doi: 10.1186/s12985-021-01642-9.
Optimization and validation of RT-LAMP assay for diagnosis of SARS-CoV2 including the globally dominant Delta variant


Vijay Lakshmi Jamwal[SUP] 1 2 [/SUP], Natish Kumar[SUP] 1 [/SUP], Rahul Bhat[SUP] 1 2 [/SUP], Piyush Singh Jamwal[SUP] 1 [/SUP], Kaurab Singh[SUP] 3 [/SUP], Sandeep Dogra[SUP] 4 [/SUP], Abhishek Kulkarni[SUP] 5 [/SUP], Bhaskar Bhadra[SUP] 5 [/SUP], Manish R Shukla[SUP] 5 [/SUP], Saurabh Saran[SUP] 1 2 [/SUP], Santanu Dasgupta[SUP] 5 [/SUP], Ram A Vishwakarma[SUP] 1 [/SUP], Sumit G Gandhi[SUP] 6 7 [/SUP]



Affiliations

Abstract

Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 pandemic, has infected more than 179 million people worldwide. Testing of infected individuals is crucial for identification and isolation, thereby preventing further spread of the disease. Presently, Taqman™ Reverse Transcription Real Time PCR is considered gold standard, and is the most common technique used for molecular testing of COVID-19, though it requires sophisticated equipments, expertise and is also relatively expensive.
Objective: Development and optimization of an alternate molecular testing method for the diagnosis of COVID-19, through a two step Reverse Transcription Loop-mediated isothermal AMPlification (RT-LAMP).
Results: Primers for LAMP were carefully designed for discrimination from other closely related human pathogenic coronaviruses. Care was also taken that primer binding sites are present in conserved regions of SARS-CoV2. Our analysis shows that the primer binding sites are well conserved in all the variants of concern (VOC) and variants of interest (VOI), notified by World Health Organization (WHO). These lineages include B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526 and B.1.617.1. Various DNA polymerases with strand displacement activity were evaluated and conditions were optimized for LAMP amplification and visualization. Different LAMP primer sets were also evaluated using synthetic templates as well as patient samples.
Conclusion: In a double blind study, the RT-LAMP assay was validated on more than 150 patient samples at two different sites. The RT-LAMP assay appeared to be 89.2% accurate when compared to the Taqman™ rt-RT-PCR assay.

Keywords: B.1.1.7 (Alpha); B.1.351 (Beta); B.1.427; B.1.429 (Epsilon); B.1.525 (Eta); B.1.526 (Iota); B.1.617.1 (Kappa); B.1.617.2 (Delta); COVID-19; Loop-mediated isothermal amplification; Molecular diagnosis; P.1 (Gamma); P.2 (Zeta); P.3 (Theta); RT-LAMP; SARS-CoV-2.
 
Back
Top Bottom